Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M143Revenue $M0.3Net Margin (%)-43,897.0Z-Score-0.2
Enterprise Value $M53.2EPS $-1.4Operating Margin %-46,697.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-43,896.0Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %-12.9Quick Ratio5.1Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %9.4Current Ratio5.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-57.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-78.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M55.7ROI % (ttm)-43.5Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 2.56-32%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 2.56-57%New holding, 81800 sh.81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.444.92view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0624.27view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.7-5.19view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.61-1.92view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.58-0.78view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.67-4.12view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.511.99view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.52.4view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-50.19view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-48.8view

Press Releases about CYTR :

    Quarterly/Annual Reports about CYTR:

    News about CYTR:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
    Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
    Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
    CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
    CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
    CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
    CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
    CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
    CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
    CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 


    More From Other Websites
    CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog Jan 26 2015
    Mettler-Toledo International Inc Earnings Call scheduled for 11:00 am ET today Jan 22 2015
    CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in... Jan 22 2015
    CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog Jan 21 2015
    Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted -... Jan 21 2015
    Ahead of the Bell: CytRx climbs as FDA lifts research hold Jan 20 2015
    Ahead of the Bell: CytRx climbs as FDA lifts research hold Jan 20 2015
    CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting... Jan 20 2015
    CytRx cancer drug shows promise in mid-stage study Jan 08 2015
    CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related... Jan 08 2015
    CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related... Jan 08 2015
    CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 06 2015
    Aegis Capital Reiterates Buy On CytRx As Stock Soars 17% Jan 06 2015
    Midday movers: Chevron, Hess, Morgan Stanley & more Jan 06 2015
    BUZZ-U.S. STOCKS ON THE MOVE-Frontline, Michael Kors, Minerva Jan 06 2015
    CytRx Reports Positive Results for Brain Cancer Treatment Jan 06 2015
    Cytrx cancer drug shows promise in mid-stage study Jan 06 2015
    CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain... Jan 06 2015
    CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain... Jan 06 2015
    Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ... Dec 15 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK